A TV channel today said MPM Capital and OrbiMed, two of the largest global healthcare funds, were in advanced stages of negotiations with the company for a strategic stake sale.
"We will divest about 10 per cent stake. We are discussing with many private equity groups and so far nothing has been finalised," said Swati Piramal, director, Nicholas Piramal. PLSL rose to Rs 296.95 at the close of trading on the Bombay Stock Exchange (BSE) from yesterday's Rs 270.55.
New drug research is a capital-intensive activity, for which the company explores from time to time various strategic funding initiatives. However, it will not comment on any reports relating to potential strategic initiatives unless they have reached the definite stage, the company informed the stock exchanges today.
The demerged company has about 14 compounds at various stages of drug development, including four in clinical trials. Clinical development of drugs requires huge expenses, about $ 1 billion in developed countries.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app